Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

5 mins

Ahmad A Aref, AGS 2022: Current Status and The Future of Microinvasive Glaucoma Surgery

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 14th 2022

It was a pleasure to speak with Professor Ahmad Aref (University of Illinois College of Medicine, Chicago, IL) to find out his thoughts in the current status and future challenges of microinvasive glaucoma surgery (MiGS) 

The presentation entitled ‘Head to Head Surgical Trials: Which MiGS? Show Me the Evidence’ was presented at the 2022 American Glaucoma Society Annual Meeting, March 03-06, 2022

Questions:

  1. Could you give us a brief overview of the current status of microinvasive glaucoma surgery (MiGS) in glaucoma management?(00:21)
  2. What factors should be considered when choosing a MiGS procedure?(01:41)
  3. What questions remain unanswered and what future studies are needed?(03:39)

Disclosures: Ahmad Aref is a consultant for Nova Eye Medical and has received grant/research support from Allergan, Inc.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.

Filmed in coverage of the virtual AGS 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup